Daily Archives: January 18, 2018

Mycobacterium avium ssp. paratuberculosis (MAP) has been suspected to play a role in Crohn disease (CD) pathogenesis. Prior studies of MAP detection in dairy cows have been more extensively investigated, successfully detecting the organisms by culture … Continue reading →

Anti-TNFα agents increase risk of infections due to systemic immunosuppression. Vedolizumab (VDZ) inhibits adhesions of gut-specific lymphocytes and thus may carry a lower risk. However, its safety in patients with prior tuberculosis (TB) infection is… Continue reading →

Crohn’s disease (CD) presents as chronic and often progressive intestinal inflammation, but the contributing pathogenic mechanisms are unclear. Our goal was to identify underlying alterations in intestinal host cells that could contribute to the chro… Continue reading →

Death receptor 3 (DR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, has been implicated in regulating T helper type 1 (TH)1, TH2 and TH17 responses as well as regulatory T cell and innate lymphoid cell functions during immune-med… Continue reading →

Health maintenance (HM) of patients with IBD is multifactorial and of well-established importance. However, the extent that it is practiced and whether the gastroenterologist (GI) or primary care provider (PP) would or should assume its responsibility … Continue reading →

ATIs develop in 8-60% of IBD patients1. Fully-humanized antibodies such as adalimumab and golimumab induce similar rates of immunogenicity, suggesting post-translational modifications as possible antigenic epitopes2. One consideration is sialylation, t… Continue reading →

Inflammatory Bowel Diseases (IBD) are characterized by upregulation of Interferon-gamma (IFN-γ). Recently we showed that IFN-γ blockade by a specific antibody in Dextran Sodium Sulfate (DSS)-colitis mouse model results in increased angiogenesis and r… Continue reading →

There are limited data guiding providers and payers on the most cost-effective position for vedolizumab (VDZ) in current ulcerative colitis (UC) treatment algorithms. Continue reading →

Crohn’s disease (CD) pathogenicity involves interplay of genetic and environmental factors (G+E). CD subjects and mice harboring ATG16L1 T300A, a key CD susceptibility allele, showed Paneth cell (PC) defects upon exposure to cigarette smoking, a known … Continue reading →

Bullous Pemphigus (BP) is a common acquired immunobullous disease. PB secondary to exposure to different drugs has been described. Mesalamines, Immunomodulators (Azathioprine, cylosporine), TNF alpha antagonists (Infliximab, Adalimumab and Etanercept),… Continue reading →